176 results on '"Massard, C."'
Search Results
2. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
3. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
4. Apport et méthodologies innovantes des essais de phase I en oncologie thoracique : des phases 1 aux essais BASKET/plateforme
5. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
6. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
7. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
8. Surveillance et adaptation de la stratégie thérapeutique en cas de progression de la maladie dans le cancer de la prostate avancé : résultats d’une enquête nationale
9. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
10. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
11. Évaluation de la réponse métabolique en TEP/TDM à la F18-FCH après un mois de traitement par acétate d’abiratérone chez les patients présentant un cancer de la prostate métastatique résistant à la castration
12. Photopolymerizable hybrid sol gel coating as a barrier against plasticizer release
13. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
14. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
15. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
16. How to select targeted therapy in renal cell cancer
17. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
18. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
19. Incidence of brain metastases in renal cell carcinoma treated with sorafenib
20. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
21. Why do residents choose the medical oncology specialty? Implications for future recruitment—results of the 2007 French Association of Residents in Oncology (AERIO) Survey
22. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
23. 2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
24. 230P Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
25. 192P Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
26. 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
27. 516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
28. The postchemotherapy PSA surge syndrome
29. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
30. Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients
31. Tumour stem cell-targeted treatment: elimination or differentiation
32. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
33. SIOG2022-0154 - Use of the Geriatric Core Dataset for older patients included in early phase trials
34. Essais précoces pour les patients porteurs de corticosurrénalomes avancés : étude rétrospective au sein du réseau endocan-comete
35. Risk factors for brain relapse in patients with metastatic breast cancer
36. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
37. 1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma
38. 472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials
39. 9P Late phase I studies: Concepts and outcomes of a new clinical trial design
40. 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma
41. 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
42. 1787P RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC
43. 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
44. 984P Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
45. 612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
46. 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
47. 1551P Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léon Bérard and Gustave Roussy experience
48. 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
49. 1452P Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center
50. 711P Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.